Yes it is mrblu,
The numbers associated with these early stage (prec-clin and Stage 1) deals is also encouraging.
The iNKT deals are good - particularly the Gilead/Kite collaboration with Appia. Appia wasn't too different to ALA before their company making deal.
I do notice that the iNKT deals were a couple of years ago and everything since has been T cell therapy based. But there are far more companies in the T-cell (and NK cell) therapies than iNKT.
Little pop in SP over the past couple of weeks has been good .
Ann: Investor Presentation, page-9
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.015(11.1%) |
Mkt cap ! $157.7M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 15.0¢ | 14.0¢ | $106.6K | 736.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 487932 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 15.36pm 16/08/2024 (20 minute delay) ? |
| ALA (ASX) Chart |